The participants were adults classified as American Society of Anesthesiologists physical status I–III who underwent elective procedures in the general, plastic and orthopedic surgery clinics of a training and research hospital in Turkey. Investigators assessed nursing care satisfaction using the Newcastle Satisfaction with Nursing Scale and postoperative recovery quality using the Quality of Recovery-40 (QoR-40), both 24 hours after surgery. The analysis included non-parametric tests, Spearman correlation analysis and simple and hierarchical multiple linear regression, with collinearity and residual diagnostics and bootstrap verification. Statistical significance was defined as p less than 0.05.

The median nursing satisfaction score was 73.68, and the median QoR-40 score was 155.0. Patients aged 66–92 years and those without health insurance had lower recovery-quality scores. Shorter preoperative hospital stays and laparoscopic procedures were associated with significantly higher QoR-40 scores. A shorter preoperative stay was also associated with higher nursing satisfaction scores (p = 0.008), whereas the difference in nursing satisfaction by surgical approach did not reach statistical significance (p = 0.051). Nursing care satisfaction correlated positively with total QoR-40 scores, including the physical comfort, emotional state and psychological support domains.

In the regression analysis, nursing care satisfaction was significantly and positively associated with postoperative recovery quality and accounted for 7.7% of the variance in QoR-40 scores, a small effect size by conventional criteria. Adding nursing satisfaction significantly improved model fit beyond the covariates alone, and the association remained significant in the fully adjusted model. That model, incorporating nursing satisfaction, age, health insurance status, preoperative hospital stay, surgical department and surgical approach, explained 23.2% of the variance in recovery-quality scores.

The findings are limited by the cross-sectional design, the sample of 131 patients, the single-hospital setting and the assessment of nursing satisfaction and recovery at the same 24-hour postoperative time point. They therefore demonstrate an adjusted association rather than a causal effect. The abstract does not report the results of any longitudinal follow-up or intervention, so the findings cannot show whether increasing nursing care satisfaction would improve postoperative recovery.

Subject of Research: Association between nursing care satisfaction and postoperative recovery quality

Article Title: Is nursing care satisfaction independently associated with postoperative recovery quality? A cross-sectional study with hierarchical regression analysis

Article References: Gümüs, K., & Kavak, T. (2026). Is nursing care satisfaction independently associated with postoperative recovery quality? A cross-sectional study with hierarchical regression analysis. BMC Nursing. https://doi.org/10.1186/s12912-026-05375-4

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05375-4

Keywords: nursing care satisfaction, postoperative recovery, cross-sectional study, surgical patients, QoR-40, hierarchical regression, patient outcomes, Turkey, nursing, care, satisfaction, independently

The China Pancreas Data Center, known as the CPDC, is a national multi-center online registration system that was initiated with the support of the Chinese Pancreatic Surgery Association, the Chinese Society of Surgery, and the Chinese Medical Association. Its purpose is straightforward: to collect standardized, prospectively entered data on pancreatic surgery from hospitals across China so that practice can be benchmarked, outcomes can be compared, and quality improvement initiatives can be grounded in evidence rather than anecdote. The newly published annual report represents a substantial step toward that goal, aggregating perioperative and survival outcomes for a patient volume that few single institutions anywhere in the world could hope to match.

The demographic and clinical profile of the 6,297 patients reflects the typical presentation of pancreatic cancer in a real-world setting. The median age at surgery was 64 years, and men outnumbered women with a male-to-female ratio of 1.2 to 1. Abdominal pain and jaundice emerged as the most common symptoms prompting diagnosis, a pattern consistent with the biology of the disease, which often remains silent until tumors grow large enough to cause obstruction or invade surrounding structures. Roughly 62.6 percent of patients presented with tumors located in the head or neck of the pancreas, the anatomical region where cancers most frequently compress the bile duct and where surgical resection, in the form of a pancreaticoduodenectomy, is among the most technically demanding operations in abdominal surgery.

One of the most closely watched metrics in modern pancreatic surgery is the adoption of minimally invasive techniques. Laparoscopic and robotic approaches have been promoted for their potential to reduce blood loss, shorten hospital stays, and speed recovery, but their role in cancer surgery depends on achieving oncological equivalence with open operations. In this national cohort, minimally invasive surgery was performed in 30.4 percent of cases, a figure that aligns with international benchmarks from high-volume pancreatic centers in Europe, North America, and East Asia. The conversion rate from minimally invasive to open surgery was 24.9 percent, a statistic that underscores the technical complexity of pancreatic resections and the importance of careful patient selection and surgeon experience in determining which approach is appropriate.

Systemic therapy played a prominent role in the treatment pathways captured by the registry. The predominant neoadjuvant and adjuvant chemotherapy regimen was nab-paclitaxel combined with gemcitabine, a doublet that has become a standard backbone for perioperative treatment of pancreatic cancer in guidelines around the world. The use of chemotherapy before and after surgery reflects a broader shift in the field, driven by clinical trials showing that multimodal treatment can improve survival even when the tumor is technically resectable. The CPDC data suggest that this paradigm has been widely integrated into Chinese surgical practice during the study period.

The safety metrics reported by the CPDC are the headline finding of the study and the numbers most likely to attract international attention. In-hospital mortality was just 0.6 percent, 30-day mortality was 1.2 percent, and 90-day mortality was 3.1 percent. For an operation historically associated with perioperative mortality rates in the double digits, these figures represent the cumulative result of decades of progress in surgical technique, perioperative care, centralization of complex surgery, and standardized postoperative management. Equally important for long-term prognosis, the one-, two-, and three-year overall survival rates reached 75.8 percent, 53.3 percent, and 42.0 percent, respectively. The authors state that these survival figures align with established benchmarks from international high-volume pancreatic centers, positioning China’s surgical outcomes for pancreatic cancer within the range of the best-performing systems worldwide.

Beyond the clinical numbers, the report offers a revealing portrait of how complex cancer surgery is organized across China’s vast and regionally uneven healthcare landscape. Nearly 45 percent of patients in the registry traveled across provincial borders to undergo their operations, a striking indicator of how far patients are willing to go to reach a surgeon or center they trust for one of the most complex operations in oncology. The authors attribute this pattern to regional disparities in medical resources rather than to patient preference alone. In advanced medical resource areas such as Beijing and Shanghai, over 99 percent of patients received their treatment locally, meaning that patients in those cities essentially never needed to leave home for surgery. The corollary is that patients in regions with fewer high-volume pancreatic surgery programs must often undertake long journeys to access equivalent care.

This geographic concentration of pancreatic cancer surgery in high-volume specialist centers carries both advantages and challenges. On the one hand, the centralization of complex procedures is widely recognized as a key driver of the low mortality and strong survival outcomes documented in the report, since outcomes in pancreatic surgery are closely tied to institutional volume and multidisciplinary expertise. On the other hand, the concentration creates access barriers for patients in less developed regions and places enormous demand on a limited number of centers. The authors emphasize the need to develop and roll out national-level benchmarks and standardized clinical protocols for pancreatic surgery across China, with the aim of raising the floor of care nationwide while preserving the strengths of the existing high-volume hubs.

The significance of the CPDC report extends beyond the borders of China. Real-world registry data of this scale are rare in pancreatic oncology, where much of the published evidence derives from single-center series, clinical trials with carefully selected populations, or national databases with variable completeness. A registry covering 65 centers and nearly 6,300 patients provides a granular view of who undergoes surgery, how the operations are performed, what perioperative therapies are delivered, and what outcomes result, all within a single standardized framework. For researchers and clinicians internationally, the report offers a benchmark against which other national systems can be compared, and for Chinese institutions it establishes a baseline for measuring the impact of future quality improvement efforts.

Pancreatic cancer accounts for a substantial and rising share of cancer deaths in China, and the demand for surgical treatment is expected to grow as the population ages and diagnostic capacity improves. The CPDC annual data report demonstrates that a coordinated national registry can capture the realities of surgical care at scale, from the adoption of minimally invasive techniques and perioperative chemotherapy to the regional patterns of patient travel and the hard endpoints of mortality and survival. As the registry continues to accumulate data in successive years, it is positioned to serve as an ongoing instrument for auditing performance, identifying gaps between centers, and guiding the standardization of pancreatic surgery across a healthcare system whose scale makes it unlike any other in the world. For the 6,297 patients whose outcomes form the backbone of this report, the findings confirm that pancreatic cancer surgery in China has reached a level of safety and effectiveness comparable to the leading international centers, while also making clear where the next phase of improvement must be directed.

Subject of Research: Real-world surgical outcomes for pancreatic cancer patients in China

Article Title: China reports real-world surgical outcomes for 6,297 pancreatic cancer patients

Article References: China reports real-world surgical outcomes for 6,297 pancreatic cancer patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, pancreatic surgery, China Pancreas Data Center, minimally invasive surgery, cancer registry, survival outcomes, Journal of Pancreatology, surgical oncology, China, reports, real-world, surgical

The technical logic behind HIFU is elegant. An extracorporeal transducer focuses multiple ultrasound beams on a target inside the fibroid, raising the temperature at the focal point high enough to induce coagulative necrosis, the irreversible thermal death of tissue, while sparing the skin, bowel, and surrounding structures along the beam path. Because the treated tissue is killed in place rather than removed, the critical question after every session is not how much tissue was excised, as it would be in surgery, but how much tissue was actually devascularized. Contrast-enhanced magnetic resonance imaging or ultrasound provides the answer in the form of the non-perfused volume ratio, or NPVR, the proportion of the fibroid volume that no longer takes up contrast agent, indicating tissue whose blood supply has been permanently interrupted. A high NPVR means the ablation covered most of the fibroid; a low NPVR means substantial viable tissue remains behind.

What the Changde team, led by Lei Dong and corresponding author Yuxin Zhou, did was to ask whether the achieved NPVR, measured immediately after treatment, actually predicts how patients fare months later. The study included 168 women with symptomatic uterine fibroids who underwent HIFU and completed six months of follow-up. For descriptive purposes, patients were sorted into three groups according to their NPVR: below 80 percent, 80 to below 90 percent, and 90 percent or above. But the analysis went far beyond simple group comparisons. The investigators used linear mixed-effects models to track longitudinal changes in symptom severity and health-related quality of life, and multivariable regression to isolate the independent contribution of NPVR after adjusting for baseline symptom scores, fibroid anatomical characteristics such as size and location, and other prespecified covariates. This statistical architecture matters, because it separates the effect of how thoroughly the fibroid was ablated from the effect of how severe the fibroid was to begin with.

The headline finding is strikingly consistent: higher achieved NPVR was associated with greater fibroid volume reduction and more favorable symptom and quality-of-life outcomes throughout follow-up. In the continuous-NPVR longitudinal analysis, the time-by-NPVR interaction was highly significant for both the Symptom Severity Scale, with F equal to 32.953 and P below 0.001, and for health-related quality of life, with F equal to 19.324 and P below 0.001. In plain terms, patients whose fibroids were more completely ablated did not merely start from a better position; their trajectories diverged over time, with the gap between high-NPVR and low-NPVR patients widening as the months passed. This is the kind of signal that clinicians look for when deciding whether an imaging marker is merely decorative or genuinely informative about clinical destiny.

The adjusted six-month analyses reinforce the same conclusion with impressive precision. After accounting for baseline outcome measures and fibroid anatomy, each increment in NPVR remained independently associated with a lower six-month Symptom Severity Scale score, with a standardized beta of minus 0.426 and a 95 percent confidence interval spanning minus 0.547 to minus 0.305, and with a higher six-month quality-of-life score, with a beta of 0.356 and a confidence interval of 0.241 to 0.471, both P below 0.001. The Symptom Severity Scale is part of the validated Uterine Fibroid Symptom and Quality of Life questionnaire, a widely used instrument in which scores of 20 points or more are considered clinically meaningful. At six months, 119 of the 168 patients, or 70.83 percent, achieved the prespecified clinical-response criterion of an SSS reduction of at least 20 points. Higher NPVR was associated with greater odds of achieving this response, with an odds ratio of 1.102 per unit increment and a confidence interval of 1.059 to 1.150.

For readers wondering whether NPVR alone can tell a clinician who will respond and who will not, the exploratory receiver operating characteristic analysis offers a sobering technical answer. The area under the curve was 0.745, with a confidence interval of 0.659 to 0.831, which the authors characterize as moderate discrimination. In practical terms, NPVR is a strong post-treatment indicator, but it is not a crystal ball. A patient with a high NPVR is more likely to respond, but the marker cannot substitute for the full clinical picture, including fibroid anatomy, baseline symptom burden, and individual healing dynamics. This nuance is important for preventing the kind of oversimplification that often accompanies viral coverage of medical imaging markers, where a single number is presented as destiny rather than as one informative variable among many.

Why does this matter so much for the future of fibroid care? HIFU is already attractive because it avoids incisions, general anesthesia in many protocols, and the prolonged recovery associated with surgery. But its Achilles heel has always been variability in ablation extent. Fibroids differ enormously in their acoustic properties, their vascularity, their distance from the skin, and their proximity to bowel or the sacrum, and operators must balance the desire for complete ablation against the risk of thermal injury to surrounding structures. The new study suggests that the achieved NPVR is not just a technical scorecard for the operator; it is a genuine predictor of how much symptom relief and quality-of-life benefit the patient will experience. That transforms NPVR from an imaging curiosity into a piece of information that can guide post-treatment counseling, follow-up intensity, and decisions about whether additional sessions or adjunctive therapies are warranted.

At the same time, the authors are emphatic about the limits of their findings, and their caution deserves equal billing with the positive results. This was a single-center retrospective cohort study, not a randomized trial, and the association between NPVR and outcomes is observational. The statistical adjustments controlled for baseline measures and anatomy, but retrospective designs cannot exclude residual confounding, and the results reflect the practice patterns and patient population of one institution. Most importantly, the investigators warn explicitly that NPVR should not be interpreted as a therapeutic target to be maximized irrespective of procedural safety. Pushing ablation extent higher can increase the risk of thermal injury to skin, bowel, nerves, or the endometrium, and the optimal balance between ablation completeness and safety must be determined in prospective studies rather than inferred from retrospective associations.

There is also a broader scientific context that makes this study more than a local quality-improvement exercise. Uterine fibroids affect a large proportion of women during their reproductive years, and the search for less invasive, fertility-preserving treatments has become one of the most active frontiers in gynecology. HIFU sits at the intersection of physics, engineering, and clinical medicine, requiring precise acoustic targeting, real-time monitoring, and careful thermal dosimetry. Studies like this one, which connect the physics of ablation to validated patient-reported outcomes, are exactly the kind of translational evidence needed to move the field from proof of concept toward personalized treatment planning. If future prospective research confirms these findings, NPVR could become a standard component of post-HIFU assessment, informing both clinical follow-up and shared decision-making between patients and physicians.

For now, the message for patients and clinicians is measured but genuinely encouraging. The Changde study provides some of the clearest retrospective evidence to date that how thoroughly a fibroid is ablated with focused ultrasound is associated with how much better patients feel and how much their quality of life improves over the following six months. It does not promise that every patient will respond, and it does not license operators to chase higher NPVR at any cost. But it does give the field a measurable, imaging-based variable that tracks with clinically meaningful benefit, and it sets the stage for the prospective trials that will determine whether NPVR can be safely optimized as part of routine fibroid care. In a specialty where the goal is increasingly to destroy disease without ever touching the body with a scalpel, that is a milestone worth noting.

Subject of Research: uterine fibroids

Article Title: Association between HIFU ablation extent and symptom relief and quality of life benefits in uterine fibroids: a retrospective analysis based on imaging and clinical indicators

Article References: Dong, L., Wang, L., Zeng, Y., Fu, W., & Zhou, Y. (2026). Association between HIFU ablation extent and symptom relief and quality of life benefits in uterine fibroids: a retrospective analysis based on imaging and clinical indicators. BMC Cancer. https://doi.org/10.1186/s12885-026-16934-y

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16934-y

Keywords: uterine fibroids, HIFU, non-perfused volume ratio, minimally invasive surgery, quality of life, medical imaging, Association, between, ablation, extent, symptom, relief

To understand why this matters, it helps to appreciate what makes lateral abdominal wall hernias so unforgiving. A hernia occurs when tissue or part of an organ pushes through a weak spot in the abdominal wall. While the most familiar hernias appear in the groin or along the midline of the abdomen, lateral hernias form along the flank, the side of the body. That location places them in a crowded and hazardous neighborhood, wedged near the ribs above, the pelvis below, and layered among the flat muscles of the abdominal wall, along with the nerves and blood vessels that run between them. Surgeons working in this region have little room to maneuver, little space to position the reinforcing mesh that strengthens the repair, and an unforgiving margin for error.

The challenge is compounded by the fact that most of these hernias do not arise spontaneously. In the new study, the majority of patients developed their hernias at the site of an earlier operation, including kidney, colorectal, spinal, or gallbladder surgery. These so-called incisional hernias emerge through the scars of previous procedures, which means the surgeon must contend not only with awkward anatomy but also with scar tissue that distorts the normal planes of the body and makes dissection more treacherous. Previous operations can fundamentally alter the landscape of the abdominal wall, leaving the surgeon to rebuild a structure whose original architecture has already been compromised.

The traditional answer to this problem has been open surgery, which can require a large incision and a correspondingly long and painful recovery. Conventional laparoscopy, or keyhole surgery, offers smaller incisions, but it comes with its own limitation in this particular territory: the rigid, straight instruments used in standard laparoscopy can be extremely difficult to articulate at the oblique angles needed to reach and repair a defect along the side of the body. The instruments simply do not bend. Working around the curve of the ribs or the crest of the pelvis with straight tools, while trying to close an opening and position a large piece of mesh flat behind the abdominal muscles, has pushed conventional keyhole techniques to their mechanical limits.

This is where the robot changes the equation. Robotic surgical systems use instruments that bend and rotate much like a human wrist, giving the surgeon degrees of freedom that rigid laparoscopic tools cannot match. The platform also provides a magnified, three-dimensional, high-definition view of the operative field, restoring the depth perception that is lost in standard two-dimensional laparoscopy. Together, these features make it easier to reach the hernia, close the defect, and place a large piece of reinforcing mesh in the retro-muscular space, behind the muscle layer, where the body’s own tissue separates the mesh from the internal organs. That positioning is considered important for long-term durability and for reducing the risk of the mesh contacting the bowel.

The study, led by Dr. Michael Freund of the Hebrew University of Jerusalem and Shaare Zedek Medical Center under the guidance of Prof. David Hazzan of Raphael Hospital, in collaboration with Sheba Medical Center and Tel Aviv University, is one of the largest investigations focused specifically on robotic repair of lateral abdominal wall hernias. The researchers emphasize that the technique they employed, a robotic transabdominal preperitoneal repair, allowed them to work in the delicate plane between the peritoneum and the abdominal wall muscles, creating room for wide mesh overlap even in an anatomically cramped region.

The team’s enthusiasm is grounded in how these outcomes compare with the published experience of similar operations. In another recent study of hernias located away from the center of the abdomen, some procedures had to be partly converted to open surgery, complications occurred in roughly one-third of patients, and some hernias recurred. In the new Israeli series, by contrast, every operation was completed robotically and no hernias returned during the follow-up period. The researchers are careful to note, however, that the two studies involved different patients and cannot be directly compared; the comparison is suggestive rather than definitive, a distinction that responsible surgical science insists upon.

“Robotic technology is changing the boundaries of what surgeons can do through small incisions,” said Dr. Freund. “In this case, it allowed us to reach one of the most unforgiving parts of the abdominal wall, an area surrounded by bone, muscle, nerves, and blood vessels, and rebuild the abdominal wall with remarkable precision. It transforms how we can approach an operation that has traditionally been exceptionally difficult.” His co-author Prof. Hazzan framed the results as the beginning of a broader shift: “We are entering a new era in which even highly complex operations can be performed with greater precision and far less disruption to the patient. In our study, every procedure was completed robotically, most patients returned home after just one day, and no hernias returned during follow-up. These are early results, but they offer a powerful glimpse of how robotic surgery could reshape complex abdominal reconstruction.”

The recovery data are as notable as the technical achievements. Most patients in the series recovered without complications and reported little pain after surgery, a reflection of the smaller incisions and reduced tissue trauma that robotic approaches can offer. Two patients did develop bowel obstructions after their operations and required a second laparoscopic procedure to resolve the problem, but both recovered fully without any part of the bowel having to be removed. Bowel obstruction is a recognized risk after any abdominal operation, and the fact that both cases could be managed laparoscopically, without open reoperation, underscores the minimally invasive ethos of the entire approach.

The researchers are candid about the limitations of their work. This was a relatively small, retrospective study, meaning it looked back at cases already performed rather than assigning patients prospectively to robotic or conventional repair, and it did not directly compare robotic surgery against other methods in a controlled fashion. Longer follow-up will also be needed to determine whether the repairs remain sound over many years, since hernia recurrence can emerge slowly over time. Even so, with 39 consecutive completions, no conversions, rapid discharges, and no recurrences at 14 months, the study stands as one of the largest of its kind and suggests that robotic technology may make these difficult operations more precise, less invasive, and dramatically easier on the patient. For the thousands of people who develop hernias along the side of the abdomen after previous surgery, the robotic wrist may prove to be exactly the tool their surgeons have been missing.

Subject of Research: Robotic-assisted repair of lateral abdominal wall hernias

Article Title: Robotic surgery enables effective and safe repair of hard-to-reach abdominal hernias

Article References: Robotic surgery enables effective and safe repair of hard-to-reach abdominal hernias. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: robotic surgery, hernia repair, lateral abdominal wall hernia, minimally invasive surgery, abdominal wall reconstruction, incisional hernia, laparoscopy, surgical mesh, transabdominal preperitoneal repair, surgical outcomes, Hebrew University of Jerusalem, Hernia journal

The case involved a patient several months out from a robotic extended totally extraperitoneal repair of an umbilical extraction-site hernia following robotic prostatectomy, combined with plication of diastasis recti, the separation of the rectus abdominal muscles. Roughly four months after the operation, the patient noticed a dense, fixed, distinctly abnormal palpable mass along his midline. The operating surgeon reviewed the imaging with a colleague, and both were unsettled by the finding. Mesh calcification seemed unlikely, and the focal, linear character of the mass did not match typical mesh-related complications. With growing uncertainty, the surgeon called a fellowship mentor, who responded without hesitation that the finding was heterotopic ossification and suggested searching the International Hernia Collaboration, a private Facebook group where surgeons connect and advance knowledge in abdominal wall surgery.

Within minutes, the search produced nine distinct posts, four of them describing nearly identical presentations after minimally invasive repair, accompanied by more than 150 comments from surgeons across the globe. These discussions detailed operative findings, technical pearls, recurrence patterns, and practical management strategies. Surgeons described encountering rigid, bone-like structures along midline repairs after minimally invasive hernia surgery, structures often mistaken initially for mesh calcification or recurrence. Only after this collective consultation did the surgeon turn to the published literature, and what emerged was sparse, dated, and almost entirely rooted in the era of open laparotomy.

Heterotopic ossification refers to the formation of bone in soft tissues where bone does not normally exist. It has long been considered a rare complication of abdominal wall surgery, most often noted in scar tissue after large laparotomies associated with trauma and vascular surgery. Yet it may be more common than assumed. Radiographic case series have reported an incidence of up to 25 percent after laparotomy, most commonly after vertical incisions and located within the linea alba, the fibrous band running down the midline of the abdomen. The published record, however, is dominated by isolated case reports and small series that establish only that ossification can occur in abdominal scars, offering limited insight into risk factors, prevention, or management, and no framework applicable to modern minimally invasive reconstruction.

Traditional etiologic theories have centered on two primary mechanisms. The first is intraoperative seeding of perichondral cells from the xiphoid process, the cartilaginous extension at the lower end of the sternum. The second is trauma-induced metaplasia, in which multipotent undifferentiated mesenchymal connective-tissue cells transform into bone-forming cells in response to injury. Both models fit the historical picture of ossification after open midline incisions near the xiphoid. They fit poorly with the emerging cases after minimally invasive hernia repair, which occur in the absence of laparotomy incisions, direct bone exposure, or overt surgical trauma, assuming as is often implied that minimally invasive surgery is inherently less traumatic.

A third, comparatively underemphasized hypothesis may be more relevant. Excessive suture-line tension, this theory proposes, may result in intramuscular implantation and subsequent ossification of periosteal particles avulsed from sites of muscular insertion into bone, with or without associated necrosis of the fascial margins. This mechanism, later emphasized in radiologic series, offers a plausible explanation for ossification observed along suture lines and in non-vertical incisions, including cesarean section scars. Extending this framework to minimally invasive abdominal wall reconstruction requires consideration of additional contributory factors, including chronic inflammatory signaling, mechanotransduction, the process by which cells convert mechanical forces into biochemical activity, and material-tissue interactions that may collectively create a permissive environment for ectopic bone formation.

Recurrent themes from the online discussions, including tensioned midline closures, barbed suture use, and retromuscular dissection planes, invite reconsideration of how mechanical forces, inflammation, and biomaterial interactions may contribute to ectopic bone formation. These observations do not establish causality, but they highlight hypotheses that would be difficult to generate from isolated cases alone. The value of the digital forum, the authors argue, lies not in replacing scientific validation but in sharpening the questions that merit rigorous investigation. The collective experience did more than identify the complication; it shaped the operative plan, informed contingency strategies including having rongeurs available to grasp and remove the bony tissue, guided patient counseling, and shaped intraoperative teaching for the resident, with the memorable warning that the finding is bone and it can be sharp.

The broader significance of the case extends beyond a single rare complication. The authors contend that surgeon-driven global communities, enabled by social media, function as powerful and underrecognized engines of early clinical discovery. These communities facilitate pattern recognition, identification of rare or emerging complications, and rapid hypothesis generation, often well before traditional publication pathways can respond. Through real-time and asynchronous discussion, surgeons across institutions and countries independently described clinical presentations, operative findings, and outcomes, and these isolated experiences converged into a recognizable pattern. What emerged was not anecdote alone but convergence, illustrating how surgeon-driven communities can function as early warning systems for rare or evolving complications.

The implications reach into practice, education, and research. Clinically, awareness of heterotopic ossification as a potential complication after minimally invasive abdominal wall surgery has immediate consequences for diagnosis, operative planning, and patient counseling. Surgeons must consider it in the differential diagnosis of postoperative midline masses or unexplained pain and be prepared for unexpected intraoperative findings. Educationally, such cases offer opportunities to teach trainees about rare complications, adaptive surgical decision-making, and the limitations of existing evidence when confronting novel presentations. From a research standpoint, early recognition through surgeon networks may represent the first step in identifying phenomena that warrant structured study; without that initial signal, many rare complications may never reach the threshold required for traditional investigation.

The authors are careful to note that these communities do not generate conclusions; they generate questions. They accelerate hypothesis formation and identify phenomena worthy of formal study, serving as a complementary pathway from observation to evidence. In an era where surgical techniques evolve faster than traditional publication cycles, the pathway from anecdote to evidence is not a leap but a process, and digital collaboration increasingly represents its earliest stage. Dismissing these platforms, the authors warn, risks delaying recognition of clinically meaningful complications and perpetuating knowledge gaps. Heterotopic ossification following minimally invasive abdominal wall surgery may remain rare, but as a case study in how modern surgical knowledge emerges, it makes a striking argument: integrating collective surgeon experience with rigorous academic inquiry can help the surgical community identify, contextualize, and study novel phenomena faster, and embracing that complementary pathway from online collaboration to clinical insight will be essential to advancing patient care in an increasingly connected surgical landscape.

Subject of Research: Surgery

Article Title: From online collaboration to clinical insight: identifying heterotopic ossification through a global hernia surgery network

Article References: Buie, V., & Jacob, B. P. (2026). From online collaboration to clinical insight: identifying heterotopic ossification through a global hernia surgery network. Journal of Abdominal Wall Surgery, 5, Article 16362. https://doi.org/10.3389/jaws.2026.16362

Image Credits: AI Generated

DOI: 10.3389/jaws.2026.16362

Keywords: hernia repair, heterotopic ossification, abdominal wall reconstruction, social media in surgery, minimally invasive surgery, International Hernia Collaboration, surgical complications, digital scholarship, online, collaboration, clinical, insight

The technical distinction at the heart of the study is more consequential than it might first appear. In minimally invasive ventral hernia repair, the mesh can be placed in several anatomical planes: intraperitoneal, where the prosthesis lies directly against the bowel within the peritoneal cavity; preperitoneal, tucked between the peritoneum and the abdominal wall; retro-muscular, positioned behind the rectus muscles; or onlay, placed superficial to the fascia. Techniques that keep the mesh outside the peritoneal cavity have been gaining popularity, largely because intraperitoneal placement carries well-documented short-term drawbacks, including increased postoperative pain driven by fixation tackers and early recurrences linked to mesh migration. Still, the most appropriate mesh position remains genuinely controversial, and the long-term consequences of each choice have never been rigorously compared.

The concern driving ORION is adhesion formation. When mesh sits intraperitoneally, it is in permanent contact with viscera, and animal studies have shown that even composite meshes designed to resist adhesion provoke fibrous bands in that space. Imaging studies and surgical revisions in these patients frequently reveal adhesions between bowel and mesh, and the clinical consequences can be serious: bowel entrapment, chronic pain, obstruction, and, most acutely, visceral injury during later operations. Surgeons performing adhesiolysis—the careful division of scar tissue—in a patient with prior intraperitoneal mesh face a landscape where loops of intestine may be densely fused to the prosthesis itself. Most existing research has focused on hernia-related outcomes such as recurrence and infection, potentially underreporting the downstream morbidity that adhesions generate over years.

The ORION investigators, a collaborative group led by researchers at the University of Milan and IRCCS Istituto Auxologico Italiano and endorsed by the European Hernia Society, have formulated a clear primary hypothesis: that prior intraperitoneal mesh placement is associated with a higher risk of intraoperative visceral injury during adhesiolysis at subsequent minimally invasive abdominal surgery than prior extraperitoneal placement. Their secondary hypotheses extend the comparison further, predicting that intraperitoneal placement brings a greater burden of adhesion-related complications, longer adhesiolysis time, higher conversion rates from minimally invasive to open surgery, and—among patients reoperated for recurrence—higher rates of chronic post-surgical pain and neuropathic features at ninety days.

The study design is deliberately pragmatic. ORION is a prospective, multicentre, observational study recruiting surgical centres across Europe, with data collection running from 1 March 2026 to 28 February 2027. Any European hospital performing elective or emergency minimally invasive abdominal surgery can participate, and there is no minimum patient quota per centre. Eligible patients are adults who previously underwent minimally invasive mesh-based ventral hernia repair—whether primary, recurrent, or incisional—with either intraperitoneal or extraperitoneal mesh, and who now require further minimally invasive abdominal surgery for any reason, from cholecystectomy to colorectal resection to gynecologic procedures. This broad capture is intentional: it reflects the real-world risk of adhesiolysis-related visceral injury across the full spectrum of abdominal operations, not just hernia redo surgery.

Participants are divided into two pre-specified cohorts. Cohort A comprises patients undergoing minimally invasive surgery for indications other than recurrent hernia repair, and these patients are assessed only up to discharge, with in-hospital outcomes recorded. Cohort B comprises patients undergoing minimally invasive repair of a recurrent ventral or incisional hernia, and this group receives scheduled follow-up at thirty and ninety days. The investigators restricted post-discharge follow-up to the recurrence cohort to prevent indication-driven heterogeneity in outcome ascertainment, a design choice that preserves internal validity for early morbidity analyses while maintaining external validity for the primary intraoperative endpoint, which is captured across all procedures performed after prior mesh placement.

The primary outcome is precisely defined: adhesiolysis-related visceral injury, meaning intraoperative damage to bowel, bladder, or solid organs during the division of adhesions. Injuries are categorized as serosal tears, full-thickness bowel injuries such as enterotomy or perforation, or other visceral injuries involving organs like the bladder, spleen, liver, or stomach. Notably, omental injury or division is considered inherent to adhesiolysis and is recorded separately rather than counted as a primary event. Secondary outcomes include the incidence of adhesion-related complications such as bowel obstruction, the duration of adhesiolysis in minutes, the rate and reasons for conversion to open surgery, and a detailed characterization of adhesions using the Peritoneal Adhesion Index, with the abdomen mapped into five regions and adhesion tenacity graded as flimsy, moderate, or dense.

For the recurrence cohort, the study digs into questions that have rarely been examined with such granularity. Investigators will document the anatomical or technical mechanism behind each hernia recurrence—central mesh failure, marginal recurrence, or mesh migration—and record how the recurrence was managed, including whether the same mesh type was reused, which anatomical plane was chosen, and which fixation methods were employed. Quality of life will be measured with the EuraHS-QoL scale at thirty and ninety days. Most distinctively, ORION incorporates validated neurological outcome measures: chronic post-surgical pain is defined as an increase of at least three points on the Visual Analogue Scale in the surgical area compared with the pre-operative baseline, new since surgery and unexplained by complications such as recurrence, infection, or obstruction. Suspected neuropathic features will be screened with the DN4 questionnaire, sensory changes around port sites will be recorded, and opioid use at day thirty will be tracked.

The statistical framework is built to detect clinically meaningful differences. A sample of 345 patients per group, 690 in total, provides ninety percent power to detect a ten percent absolute difference in adhesiolysis-related visceral injury rates, assuming an event rate of twenty-five percent in patients with prior intraperitoneal mesh and fifteen percent in those with prior extraperitoneal mesh. Relative risks will be calculated with log-binomial regression, adjusting for clinical and sociodemographic variables that differ between groups, while logistic regression models will assess associations between mesh position and chronic pain or opioid use. The investigators acknowledge the assumptions are pragmatic, drawn from available reoperation data after laparoscopic ventral hernia repair, because robust comparative estimates remain scarce.

The team is candid about the limitations inherent in an observational, non-randomized design. Because patients are identified at a subsequent operation rather than at the index repair, the study has no denominator of all originally treated patients and cannot estimate absolute risks per index procedure; the reported relative risks are conditional on reoperation and may be affected by selection bias, making the findings hypothesis-generating rather than definitive. Extraperitoneal repair is also a more recent technique, so intraperitoneal cases will tend to involve a longer interval since the original operation, and time and surgical era will be treated as covariates. Unblinded intraoperative assessment may introduce detection bias, and a twelve-month recruitment window cannot capture late complications such as adhesion-related bowel obstruction that may emerge years later. Even so, if ORION confirms that mesh position shapes the hazards of future surgery, its findings could reshape how surgeons weigh the long-term costs of intraperitoneal repair, inform the selection of mesh type and fixation strategy, and give renewed attention to the under-recognized neurological sequelae of abdominal wall reconstruction.

Subject of Research: Prospective multicentre observational study comparing long-term outcomes of intraperitoneal versus extraperitoneal mesh placement in ventral hernia repair

Article Title: The ORION study protocol: impact of prior intraperitoneal versus extraperitoneal mesh placement on subsequent minimally invasive abdominal reoperations

Article References: Pelfini, E., Lauricella, S., Nisi, A., Dionigi, G., & Brucchi, F. (2026). The ORION study protocol: impact of prior intraperitoneal versus extraperitoneal mesh placement on subsequent minimally invasive abdominal reoperations. Journal of Abdominal Wall Surgery, 5, Article 17325. https://doi.org/10.3389/jaws.2026.17325

Image Credits: AI Generated

DOI: 10.3389/jaws.2026.17325

Keywords: ventral hernia repair, mesh placement, intraperitoneal mesh, extraperitoneal mesh, adhesions, adhesiolysis, visceral injury, minimally invasive surgery, hernia recurrence, chronic post-surgical pain, European Hernia Society, observational study

Primary congenital glaucoma is a rare but relentless disease. Present from birth, it arises when the eye’s natural drainage structures fail to develop properly, allowing fluid pressure inside the eye to climb to dangerous levels. In children, this pressure does more than threaten the optic nerve; it can physically stretch the growing globe, enlarging the cornea and leaving lasting scars known as Haab striae. Keeping the pressure under control often demands an escalating series of operations over many years, and even then, some eyes stubbornly resist every conventional approach.

When angle surgery and filtration procedures fail, ophthalmologists turn to glaucoma drainage devices, small silicone tubes that shunt excess fluid from the front of the eye to a reservoir, or bleb, beneath the conjunctiva. The PAUL glaucoma implant is one of the newest members of this family. Unlike the valved Ahmed device or the larger non-valved Baerveldt, it features a flexible plate and an ultra-thin tube with a smaller internal diameter, designed to provide controlled aqueous outflow while minimizing trauma to delicate pediatric tissue. Clinical studies have shown encouraging success rates in congenital glaucoma, with pressure control achieved in roughly 67 to 87 percent of eyes at one year after implantation.

But drainage implants share a common Achilles heel: the body’s own healing response. Aqueous humor is rich in pro-inflammatory signaling molecules, and when it flows into the subconjunctival space, it can trigger an aggressive wound-healing cascade. Fibroblasts multiply, transform into contractile myofibroblasts, and lay down dense extracellular matrix, encasing the implant’s plate in a thick, low-permeability collagenous shell. Clinicians call this encapsulation, and it behaves like a balloon in a steel jacket: fluid collects but cannot disperse, and the intraocular pressure climbs back up, sometimes dramatically, in what is known as a hypertensive phase.

The patient described in the report had already endured an extraordinary surgical journey. Diagnosed with bilateral primary congenital glaucoma, she underwent deep sclerectomies in both eyes beginning in 2017. When pressure control deteriorated, she received additional procedures on each side: repeat deep sclerectomy in her right eye in 2021 followed by four sessions of micropulse cyclophotocoagulation across 2022 and 2023, and a PAUL implant in 2023. Her left eye followed a similar path, with a second deep sclerectomy in 2024 and implant placement the same year. By the time she presented in 2025, she was juggling three topical medications in one eye, two in the other, and an oral carbonic anhydrase inhibitor, all aimed at holding back pressures that medications alone could no longer master.

On admission, her left eye told the classic story of a failing implant. The pressure measured 27 millimeters of mercury despite maximal therapy. Slit-lamp examination revealed a thick capsule over a well-covered implant plate, and baseline B-scan ultrasonography confirmed a patent tube surrounded by a loculated pocket of trapped fluid, evidence that the device was working but that its outflow reservoir had been sealed off by scar tissue. Her vision held at 20/40, and the optic nerve showed moderate cupping, but the clock was ticking: sustained pressure this high in a child’s eye risks irreversible damage.

Conventional answers to encapsulation are unsatisfying. Adding more medications rarely defeats the physical barrier of a dense fibrotic shell and can further irritate an already compromised ocular surface. Placing a second implant or turning to cyclophotocoagulation lowers pressure effectively but consumes the limited conjunctival real estate that future surgeries may need. A full surgical revision carries the morbidity of another operation in an eye that has already seen many. Needle revision offers a fourth path: mechanically fenestrate the capsule through the conjunctiva, break the trapped pocket open, and use an antimetabolite such as mitomycin C to suppress the fibrotic response that caused the problem in the first place. The technique has been used in adults for decades, and a 1997 randomized trial showed it outperforming medical therapy for encapsulated blebs, but it had never been reported for a PAUL implant in a child.

Under local anesthesia and sterile conditions, the surgical team localized the encapsulated capsule and began a stepwise needling procedure with a 27-gauge needle. Before puncturing, they injected 0.3 milliliters of mitomycin C at a concentration of 0.4 milligrams per milliliter, mixed with an equal volume of 2 percent lidocaine for comfort, into the sub-Tenon’s space around the plate. The needle was then advanced through the conjunctiva to disrupt the fibrous wall, and sweeping mechanical debridement with a cotton-tipped applicator helped mobilize the trapped fluid. Subconjunctival dexamethasone was instilled at the end of the procedure, and the eye was dressed with antibiotic-steroid ointment and a protective shield.

The results unfolded rapidly. On the first day after the procedure, the pressure had already fallen from 27 to 24 millimeters of mercury, with the anterior chamber remaining deep and quiet. Nine days later, the eye showed a well-formed, diffuse drainage bleb, and the pressure had dropped into the target range of 14 to 17 millimeters. At six weeks, stabilization was excellent: pressure of 10 millimeters of mercury, vision maintained at 20/40 with isolated letters reaching 20/30, a structurally patent tube, and no inflammation inside the eye. A transient pressure spike to 22 millimeters appeared at the two-month visit, but it settled within days to 13 millimeters. The only wrinkle was a secondary ocular surface problem, superficial punctate keratitis with pinpoint corneal scars, which the team managed successfully with aggressive topical lubrication.

The authors, Abdulrahman Kaki, Jumanah Qedair, Nouf Alzendi, and Konrad Schargel, emphasize that after searching PubMed, Google Scholar, Cochrane, and Web of Science in July 2026, they found no prior report of successful needling of a PAUL implant in a child with primary congenital glaucoma. The case echoes earlier pediatric successes, including a 2020 report in which a 14-year-old boy’s failed deep sclerectomy was rescued with needle revision plus an antimetabolite, achieving a pressure of 15 millimeters without medications at one year. Together, these cases suggest that needle revision of failed filtering surgeries is a viable, tissue-preserving option in congenital glaucoma, a population in which every remaining square millimeter of healthy conjunctiva matters.

Caution is nonetheless warranted. This was a single case with a follow-up of barely two months, enough to capture the critical early window and the resolution of one transient pressure spike, but not enough to establish long-term durability, sustained pressure control, or late safety. Antifibrotic agents such as mitomycin C carry their own risks, including potential damage to the corneal epithelium and conjunctival wound leaks, and children’s healing responses can differ substantially from those of adults. The authors themselves call for prospective studies with larger cohorts and extended follow-up before the technique can be considered standard of care.

Still, the message is compelling. For a child whose eye had already absorbed deep sclerectomies, laser treatments, and two drainage implants, a needle and a drop of drug achieved what escalating surgery threatened to require: a rescued device, controlled pressure, preserved vision, and a conjunctiva left intact for whatever the future may hold. As the PAUL implant spreads into pediatric practice worldwide, this report offers surgeons a concrete, conservative playbook for one of its most common failure modes, and it reminds the field that sometimes the least invasive tool, a fine needle wielded with precision, can be the most powerful one on the tray.

Subject of Research: Needle revision with mitomycin C to treat an encapsulated bleb after PAUL glaucoma implant surgery in a pediatric patient with primary congenital glaucoma

Article Title: Case Report: Successful needle revision of an encapsulated bleb following PAUL glaucoma Implant surgery in a pediatric patient

Article References: Kaki, A., Qedair, J., Alzendi, N., & Schargel, K. (2026). Case Report: Successful needle revision of an encapsulated bleb following PAUL glaucoma Implant surgery in a pediatric patient. Frontiers in Ophthalmology, 6, Article 1952678. https://doi.org/10.3389/fopht.2026.1952678

Image Credits: AI Generated

DOI: 10.3389/fopht.2026.1952678

Keywords: glaucoma, PAUL glaucoma implant, primary congenital glaucoma, bleb needling, needle revision, mitomycin C, encapsulated bleb, glaucoma drainage device, pediatric ophthalmology, intraocular pressure, minimally invasive surgery, case report

The question the study addresses is one of the most contested in abdominal wall surgery. Obesity is a well-established driver of hernia formation and recurrence, because excess body mass raises intra-abdominal pressure, strains the abdominal wall, and impairs wound healing. Many surgeons defer elective repair above a BMI threshold, commonly 35 kilograms per square meter, despite the absence of universally accepted guidance for patients with class II or III obesity. That deferral strategy aims to reduce perioperative risk, but it can delay care in symptomatic patients, and prior research suggests that patients who are turned away often fail to return for elective repair and instead present emergently, when complication rates are nearly doubled.

Minimally invasive techniques have changed this calculus. Compared with open repair, laparoscopic and robotic approaches are associated with fewer wound complications, less postoperative pain, and shorter hospital stays. The Montefiore team used a deliberately heterogeneous mix of techniques reflecting routine academic practice: intraperitoneal onlay mesh with defect closure was the predominant operation, performed in 27 of 52 patients, followed by primary closure without mesh, intraperitoneal onlay mesh without closure, robotic enhanced-view totally extraperitoneal repair, and a small number of other approaches. Laparoscopy was used in 43 patients and robotic assistance in 9. Mesh was placed in 41 patients, with a median mesh-to-defect area ratio of 12.1, and four procedures required conversion to open or planned hybrid operations.

The cohort itself was high-risk by any measure. Mean preoperative BMI was 45.0 kilograms per square meter, 80.8 percent of patients were female, and most were American Society of Anesthesiologists class III. Diabetes was present in 46.2 percent, chronic obstructive pulmonary disease in 19.2 percent, and more than a quarter had prior bariatric surgery. Recurrent incisional hernia was the most common classification, accounting for 40.4 percent of cases, with incisional hernias making up another 30.8 percent and primary hernias 28.8 percent. Rectus diastasis, a widening of the midline abdominal muscles, was documented in 92.9 percent of patients with available imaging data.

On the primary endpoint, radiologic hernia recurrence occurred in 9 of 52 patients, or 17.3 percent, with a 95 percent confidence interval of 9.4 to 29.7 percent, at a median imaging follow-up of 793 days. The median interval from repair to the CT scan documenting recurrence was 1208 days, meaning clinically meaningful failures continued to accrue well beyond the first postoperative year. Short-term outcomes were far more favorable: the 30-day complication rate was 11.5 percent, comprising four seromas, one surgical site infection, and one abdominal wall abscess. When the analysis was broadened to include any radiologic recurrence, hernia or diastasis, the rate rose to 37.3 percent of evaluable patients, and clinical recurrence was documented in half of the 20 patients with physical examination follow-up.

The most striking pattern was a stepwise concentration of recurrence by hernia phenotype. Not a single primary hernia recurred, zero of 15, while recurrence occurred in 2 of 16 incisional hernias, 12.5 percent, and 7 of 21 recurrent incisional hernias, 33.3 percent, a difference that reached statistical significance. When primary hernias were excluded, the recurrence rate climbed to 24.3 percent. The authors frame this gradient through the vicious cycle model of ventral hernia repair, in which each successive operation leaves the abdominal wall more scarred, less vascularized, and structurally weaker, so that every subsequent repair attempt carries a progressively higher risk of failure. Under this framework, recurrent incisional hernia is not simply a more severe variant of incisional hernia but a distinct risk state shaped by the cumulative physiological toll of prior surgery, independent of BMI.

Perhaps the most unexpected finding concerned postoperative weight. Patients who developed recurrence lost significantly more weight than those who did not, a mean of 15.6 percent of total body weight versus 4.6 percent, and all nine patients with recurrence lost weight during follow-up, while 44.2 percent of patients without recurrence maintained or gained weight. The most recent BMI was lower in the recurrence group, 36.0 versus 42.6 kilograms per square meter. The authors offer a plausible mechanical explanation: substantial weight reduction alters abdominal wall mechanics and reduces tension across the repair, potentially destabilizing the mesh-tissue interface, and prior work has shown that weight change significantly impacts intra-abdominal and hernia volumes. But they are careful to note that three alternative interpretations cannot be excluded. Reverse causation is possible, since patients with subclinical recurrence may experience altered abdominal wall integrity, caloric intake, or activity that drives weight change rather than the reverse. Ascertainment bias is also possible, because patients who lose weight may be more likely to undergo repeated imaging, increasing the probability of detecting otherwise occult recurrence. And the use of most recent weight rather than a standardized timepoint may inflate between-group differences if recurrence status correlates with the duration or intensity of clinical observation.

Technical variables told a quieter story. Neither operative technique, mesh fixation method, closure suture type, posterior sheath closure, nor the mesh-to-defect area ratio demonstrated a statistically significant association with recurrence, and no patient who underwent concomitant diastasis repair developed a hernia recurrence, though only five such repairs were performed. The authors stress that these null findings should not be read as evidence that technical factors do not influence durability; with only nine events, the study was underpowered to detect such associations, and a signal for male sex, at 44.4 percent versus 14.0 percent of the recurrence and non-recurrence groups, approached but did not reach significance. All nine recurrences occurred in patients who underwent laparoscopic repair, and none among the nine robotic cases, a descriptive observation the team presents without formal inference.

The authors situate their recurrence estimate against a literature that has generally been more reassuring. An ACS-NSQIP analysis found that only a BMI of 50 or higher was independently associated with complications after minimally invasive ventral hernia repair, and a systematic review and meta-analysis of 11 studies and 3,199 patients found no significant differences in recurrence, seroma, or surgical site infection rates among patients with BMI above 40 undergoing minimally invasive repair. The higher rate observed here is likely attributable to several cohort-specific factors: prolonged and non-standardized imaging follow-up, with some patients scanned beyond three years; a high proportion of incisional and recurrent incisional hernias, 71.2 percent of the cohort; and the use of radiologic rather than clinical recurrence as the primary endpoint, which is expected to capture asymptomatic and subclinical failures. Population-based data with complete follow-up show that reoperation for recurrence after elective incisional hernia repair continues to accrue throughout five years of observation, so the 17.3 percent figure is best regarded as a lower bound on what longer, protocol-driven surveillance would reveal.

The study’s limitations are substantial and the authors are unusually candid about them. With 52 patients and nine events, all comparisons are unadjusted and exploratory, and confounding by unmeasured variables cannot be excluded. Restricting inclusion to patients with postoperative imaging may have introduced selection bias, since clinicians may have preferentially ordered CT scans in symptomatic patients, potentially inflating the observed recurrence rate. All procedures were performed by attending surgeons within a single high-volume division of minimally invasive and bariatric surgery, whose expertise in operating on patients with severe obesity likely exceeds that of general surgeons in most practice settings, so the low short-term morbidity may reflect concentrated subspecialty expertise rather than the safety of the approach at this BMI threshold more broadly. The team calls for prospective multicenter studies with protocol-driven imaging at prespecified intervals, standardized weight timepoints, and dedicated evaluation of abdominal wall biomechanics, including the apparent signal associated with concomitant diastasis repair. Until such data exist, the findings are hypothesis-generating: repair in class III obesity appears feasible with low perioperative risk, but mid-term durability, particularly in patients whose abdominal walls have already been scarred by prior surgery, remains an open question that BMI thresholds alone cannot answer.

Subject of Research: Surgery

Article Title: Radiologic recurrence after minimally invasive ventral hernia repair in patients with class III obesity: a single-center retrospective cohort study

Article References: Ahmed, A., Khalid, F., Sadeghi, A., Rodriguez Valladares, M., Flores, M., Loja Pauta, V., Alas-Pineda, C., & Mandujano, C. C. (2026). Radiologic recurrence after minimally invasive ventral hernia repair in patients with class III obesity: a single-center retrospective cohort study. Journal of Abdominal Wall Surgery, 5, Article 17051. https://doi.org/10.3389/jaws.2026.17051

Image Credits: AI Generated

DOI: 10.3389/jaws.2026.17051

Keywords: hernia recurrence, minimally invasive surgery, obesity, ventral hernia repair, weight loss, Radiologic, recurrence, minimally, invasive, ventral, hernia, repair

The research team, led by ophthalmologists at the Second Affiliated Hospital of Xi’an Medical University, enrolled 24 patients with 30 affected eyes covering the full spectrum of glaucoma subtypes: primary angle-closure glaucoma, primary open-angle glaucoma, neovascular glaucoma, and secondary glaucoma arising from other ocular diseases. Every patient had failed to achieve adequate pressure control despite maximal medical therapy. The investigators tracked outcomes at six postoperative time points—one day, one week, one month, three months, six months, and one year—measuring not only pressure itself but also 24-hour pressure fluctuation, pain scores, medication burden, and complications.

Ultrasound cycloplasty works through high-intensity focused ultrasound, the same physical principle that underlies therapeutic ultrasound in other fields of medicine. A probe coupled to the eye delivers precisely quantified acoustic energy through the sclera to the ciliary body, the ring of tissue that secretes aqueous humor, the fluid that fills the eye and determines its pressure. The energy induces controlled coagulative necrosis of the ciliary epithelium, reducing fluid production at its source. Because the energy delivery is quantifiable and the probe geometry is matched to each eye’s axial length and corneal diameter, the procedure offers a degree of targeting that older cyclodestructive techniques, such as cyclocryotherapy, never achieved.

The surgical protocol in the study reflected this precision. Each treatment sector received a fixed sonication of 22 seconds at 2.3 watts, delivering 50.65 joules per sector, with the number of sectors scaled to baseline pressure—six sectors for pressures below 30 mmHg, eight for 30 mmHg or above, and ten for 40 mmHg or higher. The nasal and temporal quadrants were deliberately left untreated to avoid the long ciliary nerves, a refinement that significantly reduces postoperative pain. The entire treatment typically lasted three to five minutes.

The efficacy results were striking. Median preoperative pressure across all 30 eyes was 40.5 mmHg; by one year it had fallen to 12 mmHg, a 59.91 percent reduction that represented the largest decrease at any time point. Primary angle-closure glaucoma patients fared best, achieving a 66.12 percent reduction at one year and a surgical success rate that reached 96.67 percent overall at final follow-up. Patients with secondary glaucoma and neovascular glaucoma also showed substantial long-term reductions, though their responses emerged more slowly, with the most pronounced decreases appearing at six months to one year rather than in the first week.

One of the study’s most clinically valuable findings was a strong positive correlation between baseline pressure and the magnitude of pressure reduction at one year, with a Spearman coefficient of 0.641. In practical terms, the higher the starting pressure, the more pronounced the lowering effect. The authors propose a mechanistic explanation: congestion and edema of the ciliary processes under high-pressure conditions may increase the sensitivity of ciliary epithelial cells to ultrasonic energy, amplifying the suppression of aqueous production. They caution, however, that a ceiling effect could exist at extreme pressures, where the compensatory imbalance between fluid production and outflow might blunt the treatment’s effectiveness.

Perhaps the most innovative contribution of the study was its use of the mean amplitude of intraocular pressure excursion, or MAPE, as a dynamic efficacy indicator. Unlike single-timepoint measurements, MAPE captures clinically meaningful pressure drift over a full 24-hour cycle by filtering out minor physiological variations below a standard-deviation threshold. Before surgery, the mean MAPE was 10.6; one day after treatment it had halved to 5.3, a statistically significant improvement. The authors interpret this as evidence that ultrasound cycloplasty stabilizes pressure through a dual mechanism: focused ultrasound thermocoagulation suppresses aqueous production, while collagen remodeling enhances the patency of outflow channels.

Safety outcomes were equally reassuring. Transient conjunctival hyperemia occurred in 86.7 percent of eyes within 24 hours but resolved within days, and anterior chamber inflammation appeared in 46.7 percent without fibrinous exudation or synechiae. Pupillary irregularities developed in 40 percent of cases but stabilized within two weeks, often with short-term miotic therapy. Critically, no cases of profound hypotony, choroidal detachment, macular edema, or phthisis bulbi were observed during the entire follow-up period—complications that have been reported with older cyclodestructive approaches. Pain scores, measured on a numerical rating scale, fell from a median of 5 preoperatively to 1 at one year, suggesting long-term relief of glaucoma-related discomfort.

The study’s authors conclude that postoperative pressure stabilizes by three months, allowing gradual withdrawal of medications, and they position ultrasound cycloplasty as a reliable option across glaucoma subtypes. They acknowledge limitations, including the modest sample size, the single-center design, and the lack of between-eye correlation adjustment in patients with both eyes enrolled. They call for multicenter trials with larger cohorts, particularly for neovascular and refractory glaucoma, and suggest extending dynamic monitoring beyond 24 hours in selected patients.

For a disease projected to affect more than 111.8 million people by 2040, the findings carry real weight. Ultrasound cycloplasty cannot restore vision already lost to glaucoma, but by offering a repeatable, precisely dosed, and well-tolerated way to bring pressure under control—even in eyes where filtration surgery has failed or is anatomically unsuitable—it adds a genuinely minimally invasive weapon to the ophthalmologist’s arsenal. The Northwest China data, with their unprecedented attention to 24-hour pressure dynamics and long-term safety, suggest that the technique deserves a place in precision treatment algorithms for glaucoma worldwide.

Subject of Research: Ophthalmology

Article Title: Ultrasound cycloplasty: dynamic efficacy and long-term safety in glaucoma patients from northwest China

Article References: Ge, P., Shi, R., Mu, Q.-Q., Zhang, R.-X., Yang, X.-X., & He, Y. (2026). Ultrasound cycloplasty: dynamic efficacy and long-term safety in glaucoma patients from northwest China. Frontiers in Medicine, 13, Article 1819637. https://doi.org/10.3389/fmed.2026.1819637

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1819637

Keywords: glaucoma, ultrasound cycloplasty, high-intensity focused ultrasound, intraocular pressure, minimally invasive surgery, ophthalmology, Frontiers in Medicine, Ultrasound, cycloplasty, dynamic, efficacy, long-term

The clinical problem the team set out to solve is both common and stubborn. Roughly 50,000 people in the United States develop endocarditis each year, an infection of the heart’s inner tissue that can destroy valves and seed dangerous clots throughout the circulation. The standard treatment is a course of intravenous antibiotics lasting four to six weeks, but the therapy frequently falls short because the drugs become heavily diluted as they circulate through the entire body before reaching the heart. By the time the medication arrives at the infected tissue, the concentration may be too low to clear the bacteria effectively.

When intravenous therapy fails, physicians are left with two unattractive options. One is to escalate to higher and higher doses of antibiotics, which risks toxicity to organs such as the kidneys and can still fail to reach therapeutic levels inside the heart. The other is open-heart surgery, a highly invasive procedure in which the chest is opened and the heart may be stopped and placed on bypass, exposing the patient to blood loss, infection, and long recovery. The Johns Hopkins team, led by senior author Axel Krieger, a medical roboticist previously known for developing robots that performed a realistic surgical procedure without human assistance, wanted a way to sidestep both paths entirely.

Their answer is a pair of magnetically powered devices the researchers call millirobots, named for their scale: each is about as wide as a pencil tip or the head of a matchstick and roughly as long as a grain of rice. Rather than a single larger robot, the system uses two specialized modules that work in tandem. The first, called the needle module, is guided to the infected site, where it gently latches onto the heart tissue and remains in place. Anchored to the moving muscle, it serves as a docking station on the surface of the beating heart, waiting for its partner to arrive.

The second device, the drug module, carries the medication payload. It navigates through the body to the waiting needle module and magnetically docks with it, then slowly releases antibiotics at the precise location where they are most needed. The two-robot architecture solves several problems at once. Because the modules are small, the system can reach tight anatomical spaces that a single larger device could not. And because the needle module stays docked while the drug module can detach and be replaced, clinicians can administer repeat doses of medicine without re-navigating the entire system, a feature that could prove essential when a single round of treatment is not enough.

Both robots contain no batteries, no motors, and no onboard power source of any kind. Instead, they are made of magnetic materials and steered wirelessly by an external electromagnetic coil system that operates on principles similar to those of an MRI machine. The coils generate controlled magnetic fields and gradients that pull and rotate the robots through the vasculature and hold them steady against the motion of the beating heart. Magnetic guidance is exciting, Krieger explained, because the robot itself carries nothing that can fail or harm the patient; the same field technology used for imaging in hospitals becomes the engine that drives the millirobots to their target.

The team tested the system on phantom heart models engineered to closely mimic human cardiac anatomy, as well as on real porcine heart tissue. In these experiments the robots traveled smoothly and autonomously, even when moving against simulated blood flow, demonstrating that the magnetic control scheme can overcome the hemodynamic forces that would sweep a passive object away. The success in both synthetic and biological tissue is an important early milestone, though the researchers emphasize that more realistic testing lies ahead before the technology approaches the clinic.

The potential payoff in treatment time is dramatic. Anuruddha Bhattacharjee, first author of the study and a former Johns Hopkins postdoctoral researcher who is now an assistant professor at the University of Alabama at Birmingham, described a future in which a patient receives a tiny robot through a simple injection into a vein, after which it travels to the infection site with minimal invasiveness. Where conventional intravenous therapy demands four to six weeks of hospital or at-home drug administration, the robotic procedure might take as little as ten minutes, or perhaps an hour if several rounds of dosing are required. If everything works as designed, Bhattacharjee noted, the treatment timeline collapses from weeks to a single day or less, delivered through what amounts to a pinprick rather than a sawn-open chest.

Krieger frames the work as the frontier of surgical robotics, and the implications extend well beyond cardiology. Because the platform delivers concentrated drugs to a precisely chosen location, the researchers believe it could be adapted to fight cancer where it is spreading, saturating tumors with chemotherapy while sparing healthy tissue the toxic systemic exposure that limits conventional dosing. Any disease that is difficult to reach with oral or intravenous drugs, from deep-seated infections to localized malignancies, is a candidate for the same docking-and-release strategy, and the steerable robots could play a major role across those applications.

Significant engineering and clinical hurdles remain before pencil-tip robots are injected into patients. The researchers’ next step is to test the devices in more realistic phantom hearts that reproduce the muscular contraction and beating movement of a living heart, conditions that will stress the docking mechanism and the magnetic control algorithms far more than the current models did. Human trials, regulatory review, and manufacturing at clinical scale all lie further down the road. But the demonstration that two untethered, battery-free robots can navigate simulated blood flow, latch onto moving cardiac tissue, dock magnetically, and release medication on target marks a striking proof of concept, one that hints at a future in which the most dangerous heart surgery is performed by machines smaller than a grain of rice, guided from outside the body and removed without a scar.

Subject of Research: Magnetically steered millirobots for targeted drug delivery to infected heart tissue

Article Title: Tiny robots speed medicine through body to the heart

Article References: Tiny robots speed medicine through body to the heart. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: millirobots, medical robotics, endocarditis, targeted drug delivery, magnetic steering, Johns Hopkins University, Advanced Materials Technologies, minimally invasive surgery, antibiotics, heart infection, electromagnetic coils, cancer therapy